ORIC® Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Company Overview - ORIC Pharmaceuticals, Inc. is a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance [3] - The company has two main clinical stage product candidates: ORIC-114, targeting EGFR and HER2 mutations in genetically defined cancers, and ORIC-944, an allosteric inhibitor for prostate cancer [3] - ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms [3] Upcoming Event - Jacob M. Chacko, M.D., the CEO of ORIC, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025, at 11:15 a.m. PT [1] - A live webcast of the presentation will be available on the company's investor website, with a replay accessible for 90 days post-event [2]